TLSI
TriSalus Life Sciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$5.10
+4.08%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.91
From 52W high−32.00%
Volume605909.00
Market cap$314.03M
P/E (TTM)—
P/S (TTM)7.0x
Div yield—
Key dataSep 18, 2026
Open
$4.91
From 52W high
−32.00%
Volume
605909.00
Market cap
$314.03M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.9x
P/E (TTM)
—
RSI (14)
47.8
MomentumView details →
1D Return
+4.08%
YTD Return
−30.66%
SummaryUpdated Jun 1, 2026
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is a medical device and immunotherapy company founded in 2017 and based in Westminster, Colorado. The company went public in February 2021 and specializes in developing innovative treatment technologies for liver and pancreatic cancers. TriSalus has established itself as a pioneer in pressure-enabled drug delivery (PEDD) technology, which allows for more targeted and effective treatment of solid tumors through specialized infusion systems.
Similar companies
Latest newsMore news →
TriSalus reported a significant revenue miss and lowered its guidance during Q2 2026, citing a Salesforce reorganization and delayed FDA review of its next-generation device.44d agoTriSalus Life Sciences announced its financial results for the quarter ended June 30, 2026, reporting year-over-year and sequential growth.45d ago